Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Crohn's disease
Pharma
Lilly's Omvoh bests J&J's Stelara in Crohn's study
Eli Lilly's drug outperformed Johnson & Johnson's established Stelara in a phase 3 study that looked at histologic disease responses over 52 weeks.
Zoey Becker
Oct 14, 2024 12:15pm
Subcutaneous version of J&J's Tremfya excels in Crohn's trial
Jun 20, 2024 11:12am
UPDATED: J&J readies Tremfya for IBD showdown with AbbVie, Lilly
May 21, 2024 9:49am
Lilly pads case for mirikizumab in its next potential indication
May 21, 2024 9:20am
Celltrion signs 'The Traitors' star for bowel disease campaign
May 20, 2024 10:10am
BMS' Zeposia comes up short in Crohn's disease study
Mar 29, 2024 8:15am
